What are co-occurring disorders?
Co-occurring disorders (also called dual diagnosis or comorbidity) exist when a substance use disorder and a mental health disorder are present at the same time. Common co-occurring combinations include:
- Depression + Alcohol Use Disorder: Approximately 30-40% of individuals with AUD have a co-occurring depressive disorder. Alcohol is a CNS depressant that worsens depressive symptoms over time.
- PTSD + Opioid Use Disorder: An estimated 60-80% of individuals with opioid use disorder have experienced significant trauma. Opioids are often used to self-medicate trauma symptoms — numbing, avoidance, and hyperarousal.
- Anxiety Disorders + Benzodiazepine Dependence: Benzodiazepines are frequently prescribed for anxiety, but chronic use produces dependence and ultimately worsens anxiety through withdrawal-mediated rebound.
- Bipolar Disorder + Substance Use: Approximately 56% of individuals with bipolar I disorder have a lifetime substance use disorder — one of the highest comorbidity rates of any psychiatric condition.
- ADHD + Stimulant Misuse: Individuals with untreated ADHD are 2-3 times more likely to develop a substance use disorder, often beginning with self-medication using stimulants.
The relationship between mental illness and substance use is bidirectional. Mental health conditions increase vulnerability to addiction (self-medication), and substance use can trigger or worsen psychiatric symptoms. Both conditions share overlapping neurobiological risk factors including genetic vulnerability, brain reward circuitry dysfunction, and stress-response dysregulation.
Why must both conditions be treated simultaneously?
Treating substance use without addressing the co-occurring mental health condition — or vice versa — produces significantly worse outcomes. The evidence is clear:
- Individuals with untreated co-occurring disorders have relapse rates 2-3 times higher than those receiving integrated treatment
- Sequential treatment (treating addiction first, then mental health, or vice versa) is associated with higher dropout rates, treatment failure, and psychiatric crisis
- Untreated depression or anxiety in individuals with substance use disorder increases suicidality, hospitalization, and emergency department utilization
- Untreated substance use in individuals with mental illness reduces medication adherence, worsens psychiatric symptoms, and increases functional impairment
SAMHSA's Treatment Improvement Protocol (TIP) 42 establishes integrated treatment as the standard of care for co-occurring disorders. This means a single clinical team addresses both conditions with a unified treatment plan — not separate providers working in isolation.
At Ascend, the same therapist, psychiatrist, and clinical team manage both the addiction and the psychiatric condition. Treatment plans are coordinated, medication decisions account for both diagnoses, and therapeutic interventions address the interaction between conditions.
Questions About Why must both conditions?
Call our 24/7 admissions line or verify your insurance online.
What does integrated dual diagnosis treatment look like at Ascend?
Ascend's dual diagnosis program combines addiction treatment with psychiatric care delivered by a unified clinical team:
- Comprehensive psychiatric evaluation: Thorough diagnostic assessment using DSM-5 criteria for both substance use and psychiatric disorders. Includes clinical interview, psychological testing when indicated, medical history review, and collateral information gathering.
- Integrated treatment planning: A single treatment plan addressing both conditions, with measurable goals, evidence-based interventions, and coordinated medication management.
- Individual therapy: CBT for both substance use and psychiatric symptoms, EMDR for trauma and PTSD, DBT for emotional dysregulation and borderline personality features, and motivational interviewing for treatment engagement.
- Medication management: Psychiatric medications (antidepressants, mood stabilizers, antipsychotics, non-addictive anxiolytics) and MAT for substance use disorder (buprenorphine, naltrexone), prescribed and managed by the same psychiatric team.
- Specialized group therapy: Groups addressing the intersection of mental health and addiction — understanding the self-medication cycle, developing non-substance coping strategies, and building psychiatric symptom management skills.
- Family therapy: Education on co-occurring disorders, communication skills, boundary setting, and the family's role in supporting recovery from both conditions.
“You cannot treat addiction in isolation from mental health, and you cannot treat mental health in isolation from addiction. These conditions feed each other. The only effective approach is integrated treatment by a unified clinical team that understands both diagnoses and their interaction.”
How is dual diagnosis diagnosed and assessed?
Accurate diagnosis of co-occurring disorders requires clinical expertise, because substance use can mimic, mask, or exacerbate psychiatric symptoms.
Challenges in dual diagnosis assessment:
- Substance-induced disorders vs. independent disorders: Cocaine can produce symptoms indistinguishable from mania. Alcohol withdrawal mimics generalized anxiety. Methamphetamine psychosis resembles schizophrenia. Clinicians must determine whether psychiatric symptoms are substance-induced, pre-existing, or both.
- Timeline analysis: Establishing whether psychiatric symptoms preceded substance use (suggesting an independent disorder), occurred only during active use (suggesting substance-induced), or worsened significantly with substance use (suggesting interaction).
- Observation over time: Some psychiatric diagnoses require a period of sustained abstinence (typically 2-4 weeks) for accurate assessment. This is why PHP-level care is valuable — it provides extended clinical observation.
Ascend uses validated assessment tools including the PHQ-9 (depression), GAD-7 (anxiety), PCL-5 (PTSD), MDQ (bipolar spectrum), and substance use screening instruments. These are complemented by clinical interview and, when indicated, comprehensive psychological testing.
